Autopsy report · NCT00283842

Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy

“business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 3 months before it stopped.
• 408 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Sponsor type

Industry

Conditions

Diabetic Neuropathies; Pain

Interventions

DVS SR; Placebo

Participants

408

Sites

51

Countries

United States

Trials that died the same way

• PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin
  “Business reason” (94% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (88% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (87% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (85% match in meaning)
• Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass
  “For business reasons” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.